GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Current Accrued Expense

INKT (MiNK Therapeutics) Current Accrued Expense : $4.63 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Current Accrued Expense?

MiNK Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2024 was $4.63 Mil.

MiNK Therapeutics's quarterly Current Accrued Expense increased from Dec. 2023 ($5.04 Mil) to Mar. 2024 ($5.28 Mil) but then declined from Mar. 2024 ($5.28 Mil) to Jun. 2024 ($4.63 Mil).

MiNK Therapeutics's annual Current Accrued Expense increased from Dec. 2021 ($1.76 Mil) to Dec. 2022 ($4.24 Mil) and increased from Dec. 2022 ($4.24 Mil) to Dec. 2023 ($5.04 Mil).

MiNK Therapeutics Current Accrued Expense Historical Data

The historical data trend for MiNK Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Current Accrued Expense Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
2.59 1.54 1.76 4.24 5.04

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.24 3.85 5.04 5.28 4.63

MiNK Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

MiNK Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Current Accrued Expense
Comparable Companies
COEP PASG HOOK NERV SLGL GANX PVCT VTVT EFTR CGTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Website
https://www.minktherapeutics.com
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010